Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy

The presence of anti-John Cunningham Virus (JCV) antibodies is a risk factor for the development of progressive multifocal leukoencephalopathy (PML) in MS patients treated with natalizumab. It has been suggested that an increase in serum anti-JCV antibody index precedes the development of PML. We he...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2015-10, Vol.21 (12), p.1600-1603
Main Authors: Vennegoor, Anke, van Rossum, Johannis A, Polman, Chris H, Wattjes, Mike P, Killestein, Joep
Format: Article
Language:English
Subjects:
Adult
Antibodies
Antibodies, Viral - blood
Encephalitis
Female
Humans
Immunoglobulins
Immunologic Factors - adverse effects
Immunotherapy
JC Virus - immunology
Leukoencephalopathy
Leukoencephalopathy, Progressive Multifocal - blood
Leukoencephalopathy, Progressive Multifocal - chemically induced
Male
Monoclonal antibodies
Multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting - blood
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Natalizumab - adverse effects
Patients
Progressive multifocal leukoencephalopathy
Risk factors
Serology
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The presence of anti-John Cunningham Virus (JCV) antibodies is a risk factor for the development of progressive multifocal leukoencephalopathy (PML) in MS patients treated with natalizumab. It has been suggested that an increase in serum anti-JCV antibody index precedes the development of PML. We here describe extensive longitudinal serum anti-JCV antibody indexes of four MS patients who developed PML. Anti-JCV antibodies were measured using the STRATIFY JCV™DxSelect™ test. All four patients had rather stable high anti-JCV antibody indexes in all samples obtained before developing PML. Possibly caused by reaching the saturation level of the assay, no increase in anti-JCV antibody indexes was seen just before the diagnosis of PML. This study confirms that high serum anti-JCV antibody indexes precede natalizumab-associated PML.
ISSN:1352-4585
1477-0970
DOI:10.1177/1352458514567728